Hospital
Kaiser Foundation Hospitals
Kaiser Foundation Hospitals was paid $76.49M by Medicaid between Jan 2018 and Dec 2024, across 344 billing codes. Its largest line is 99283, emergency room visit (moderate) — 16% of everything it billed.
33Billing provider infoKAISER FOUNDATION HOSPITALS
HONOLULU, HI 96819
HONOLULU, HI 96819
33aNPI1396813861assigned 12/01/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$76.49M
24GClaims1,754,687
24DCodes billed344
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Hawaii
Rank by total paid#1 of 18
Median peer was paid$10.94M
This provider vs. median7.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 223,418 | $5.60M | |
| 2019 | 205,963 | $7.42M | |
| 2020 | 161,110 | $7.59M | |
| 2021 | 235,570 | $10.77M | |
| 2022 | 307,991 | $12.57M | |
| 2023 | 310,420 | $14.74M | |
| 2024incomplete | 310,215 | $17.78M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 38,102 | 34,395 | $12.00M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.3% | 12,534 | 11,041 | $6.34M |
| 84443 | Thyroid stimulating hormone (TSH) | 5.7% | 40,382 | 39,011 | $4.36M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4.9% | 27,293 | 26,273 | $3.79M |
| G0378 | Hospital observation service, per hour | 4.3% | 3,588 | 2,784 | $3.31M |
| 80061 | Lipid panel | 4.2% | 40,604 | 39,986 | $3.19M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 4.0% | 27,111 | 26,103 | $3.02M |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 3.6% | 12,366 | 12,145 | $2.78M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.4% | 3,784 | 3,591 | $2.57M |
| 87481 | 3.3% | 3,256 | 3,137 | $2.56M | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.7% | 11,551 | 11,349 | $2.10M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.6% | 35,149 | 30,946 | $2.02M |
332 more codes
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 2.5% | 10,007 | $1.88M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2.1% | 12,122 | $1.62M |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.6% | 9,157 | $1.21M |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.5% | 76,934 | $1.16M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.2% | 1,055 | $918K |
| 83970 | 1.1% | 3,611 | $878K | |
| 83880 | 1.1% | 7,113 | $874K | |
| 86803 | 1.1% | 20,543 | $865K | |
| 87505 | 1.0% | 1,883 | $778K | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 1,341 | $763K |
| 84153 | <1% | 5,955 | $707K | |
| 82274 | <1% | 14,211 | $707K | |
| 99285 | Emergency room visit (most serious) | <1% | 931 | $680K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 6,582 | $627K |
| 80348 | <1% | 1,904 | $556K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,019 | $554K |
| 82670 | <1% | 2,542 | $532K | |
| 86480 | <1% | 1,384 | $511K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 55,689 | $446K |
| 88341 | <1% | 1,093 | $444K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 16,467 | $413K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,177 | $391K |
| 87186 | <1% | 8,752 | $357K | |
| 82570 | <1% | 25,364 | $353K | |
| 83718 | <1% | 22,211 | $341K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 975 | $296K |
| 87088 | <1% | 22,905 | $293K | |
| 83655 | <1% | 7,221 | $289K | |
| 82728 | <1% | 8,623 | $287K | |
| 87536 | <1% | 400 | $282K | |
| 82043 | <1% | 18,626 | $275K | |
| 80051 | <1% | 61,056 | $275K | |
| 80069 | <1% | 1,729 | $270K | |
| 87517 | <1% | 1,234 | $251K | |
| 85027 | <1% | 34,222 | $247K | |
| 87650 | <1% | 6,188 | $228K | |
| 88142 | <1% | 14,508 | $217K | |
| 83721 | <1% | 24,418 | $215K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 24,481 | $214K |
| 81511 | <1% | 1,091 | $212K | |
| 84403 | <1% | 3,049 | $211K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 285 | $203K |
| 81329 | <1% | 972 | $197K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 489 | $187K |
| 80305 | <1% | 15,227 | $186K | |
| 82105 | <1% | 2,254 | $185K | |
| 82607 | <1% | 8,243 | $173K | |
| 87070 | <1% | 6,144 | $144K | |
| 86003 | <1% | 421 | $137K | |
| 86677 | <1% | 1,831 | $110K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,654 | $109K |
| 82378 | <1% | 1,319 | $104K | |
| 80346 | <1% | 344 | $101K | |
| 88342 | <1% | 2,242 | $99K | |
| 84702 | <1% | 3,599 | $98K | |
| 86160 | <1% | 754 | $94K | |
| 86850 | <1% | 7,206 | $93K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 234 | $93K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 180 | $92K |
| 86780 | <1% | 6,130 | $89K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 295 | $86K |
| 87081 | <1% | 5,629 | $86K | |
| 84146 | <1% | 2,366 | $84K | |
| 83735 | <1% | 15,336 | $82K | |
| 80354 | <1% | 2,985 | $80K | |
| 93017 | <1% | 738 | $69K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,820 | $68K |
| 84460 | <1% | 69,357 | $65K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 381 | $64K |
| 87040 | <1% | 3,859 | $63K | |
| 84466 | <1% | 6,429 | $62K | |
| 80053 | Comprehensive metabolic panel | <1% | 228 | $62K |
| 88143 | <1% | 4,482 | $61K | |
| 86762 | <1% | 3,999 | $59K | |
| 87625 | <1% | 473 | $59K | |
| 73110 | <1% | 1,549 | $59K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 3,322 | $57K |
| 86704 | <1% | 5,146 | $57K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 411 | $56K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,386 | $56K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 941 | $56K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 705 | $53K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,974 | $51K |
| 86304 | <1% | 583 | $50K | |
| 73630 | <1% | 2,244 | $50K | |
| 73564 | <1% | 1,232 | $50K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,064 | $50K |
| 84165 | <1% | 1,050 | $49K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 328 | $49K |
| 86300 | <1% | 310 | $47K | |
| 73610 | <1% | 1,703 | $47K | |
| 88307 | <1% | 230 | $46K | |
| 82784 | <1% | 1,679 | $45K | |
| 86665 | <1% | 147 | $44K | |
| 87522 | Neg quan hep c or qual rna | <1% | 213 | $44K |
| 88304 | <1% | 1,006 | $42K | |
| 80349 | <1% | 1,442 | $40K | |
| 73130 | <1% | 1,489 | $40K | |
| 87075 | <1% | 1,231 | $36K | |
| 85610 | <1% | 13,484 | $35K | |
| 86038 | <1% | 2,236 | $35K | |
| 83690 | <1% | 11,658 | $34K | |
| 80362 | <1% | 113 | $32K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 79 | $32K |
| 82150 | <1% | 2,081 | $27K | |
| 84425 | <1% | 832 | $26K | |
| 82951 | <1% | 661 | $26K | |
| 82565 | <1% | 74,299 | $26K | |
| 82533 | <1% | 434 | $25K | |
| 83001 | <1% | 2,481 | $24K | |
| 82247 | <1% | 30,778 | $23K | |
| 87338 | <1% | 441 | $22K | |
| 82977 | <1% | 2,045 | $21K | |
| 86696 | <1% | 402 | $19K | |
| 86235 | <1% | 38 | $19K | |
| 88141 | <1% | 966 | $18K | |
| 83516 | <1% | 367 | $18K | |
| 82310 | <1% | 12,794 | $18K | |
| 85014 | <1% | 2,860 | $18K | |
| 73140 | <1% | 445 | $18K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,109 | $17K |
| 86140 | <1% | 9,297 | $17K | |
| 87420 | <1% | 511 | $17K | |
| 88108 | <1% | 148 | $17K | |
| 73030 | <1% | 871 | $17K | |
| 82627 | <1% | 249 | $16K | |
| 86900 | <1% | 7,877 | $16K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,595 | $15K |
| 73080 | <1% | 442 | $15K | |
| 83615 | <1% | 3,186 | $13K | |
| 86787 | <1% | 3,529 | $13K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,753 | $13K |
| 84550 | <1% | 12,340 | $12K | |
| 81001 | <1% | 16,384 | $12K | |
| 82950 | <1% | 3,312 | $12K | |
| 87449 | <1% | 681 | $11K | |
| 80361 | <1% | 3,225 | $10K | |
| 81025 | <1% | 8,988 | $10K | |
| 80324 | <1% | 312 | $10K | |
| 83520 | <1% | 188 | $10K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,332 | $9K |
| 80373 | <1% | 1,448 | $9K | |
| 82550 | <1% | 3,637 | $9K | |
| 86765 | <1% | 3,203 | $9K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 113 | $9K |
| 84075 | <1% | 24,318 | $8K | |
| 86225 | <1% | 601 | $8K | |
| 84484 | <1% | 9,839 | $7K | |
| 88312 | <1% | 28 | $7K | |
| 87255 | <1% | 59 | $7K | |
| 84445 | <1% | 12 | $7K | |
| 70486 | <1% | 42 | $7K | |
| 85379 | <1% | 2,221 | $7K | |
| 73221 | <1% | 25 | $6K | |
| 86359 | <1% | 233 | $6K | |
| 84703 | <1% | 2,503 | $6K | |
| 84439 | <1% | 16,621 | $6K | |
| 85730 | <1% | 8,234 | $6K | |
| 86706 | <1% | 5,248 | $6K | |
| 87252 | <1% | 42 | $6K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,958 | $6K |
| 87177 | <1% | 1,004 | $6K | |
| 84134 | <1% | 570 | $5K | |
| 84480 | <1% | 1,826 | $5K | |
| 87340 | <1% | 11,414 | $5K | |
| 87529 | <1% | 12 | $5K | |
| 82248 | <1% | 1,331 | $5K | |
| 83605 | <1% | 3,008 | $4K | |
| 82947 | <1% | 9,648 | $4K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,049 | $4K |
| 83021 | <1% | 38 | $4K | |
| 71045 | Radiologic examination, chest; single view | <1% | 6,100 | $4K |
| 86735 | <1% | 55 | $4K | |
| 84450 | <1% | 41,369 | $4K | |
| 86308 | <1% | 592 | $4K | |
| 73502 | <1% | 87 | $4K | |
| 93271 | <1% | 39 | $4K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 451 | $3K |
| 86592 | <1% | 7,345 | $3K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 5,975 | $3K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,277 | $3K |
| 86923 | <1% | 48 | $3K | |
| 82040 | <1% | 11,021 | $3K | |
| 82077 | <1% | 948 | $3K | |
| 87101 | <1% | 155 | $3K | |
| 86200 | <1% | 170 | $3K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 281 | $3K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 168 | $3K |
| 12001 | <1% | 40 | $2K | |
| 84132 | <1% | 876 | $2K | |
| 86708 | <1% | 560 | $2K | |
| 80321 | <1% | 2,837 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,264 | $2K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 13 | $2K |
| E0603 | Breast pump, electric (ac and/or dc), any type | <1% | 79 | $2K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 42 | $2K |
| 81479 | Unlisted molecular pathology procedure | <1% | 12 | $2K |
| 81513 | <1% | 3,192 | $2K | |
| 74018 | <1% | 317 | $2K | |
| 87329 | <1% | 117 | $2K | |
| 93308 | <1% | 12 | $2K | |
| 83993 | <1% | 12 | $1K | |
| 84144 | <1% | 142 | $1K | |
| 76830 | Ultrasound, transvaginal | <1% | 125 | $1K |
| 36592 | <1% | 17 | $1K | |
| 86800 | <1% | 300 | $1K | |
| 77003 | <1% | 133 | $1K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 404 | $1K |
| 87493 | <1% | 70 | $1K | |
| 81003 | <1% | 3,340 | $1K | |
| 87184 | <1% | 3,663 | $1K | |
| 86431 | <1% | 1,409 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,336 | $1K |
| 81000 | <1% | 172 | $969.71 | |
| 87324 | <1% | 605 | $968.18 | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 19 | $928.36 |
| 82785 | <1% | 82 | $920.00 | |
| 85652 | <1% | 7,410 | $919.74 | |
| 83002 | <1% | 981 | $881.95 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,206 | $830.32 |
| 86376 | <1% | 455 | $786.81 | |
| 84520 | <1% | 23,465 | $767.88 | |
| 82746 | <1% | 7,825 | $767.81 | |
| 83521 | <1% | 25 | $732.00 | |
| 80320 | <1% | 199 | $718.99 | |
| 84156 | <1% | 8,781 | $697.48 | |
| 73590 | <1% | 46 | $696.76 | |
| 84100 | <1% | 5,930 | $696.46 | |
| 76000 | <1% | 231 | $681.00 | |
| 85045 | <1% | 715 | $656.45 | |
| 81002 | <1% | 87 | $647.85 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,757 | $563.01 |
| 73000 | <1% | 14 | $504.00 | |
| 71250 | <1% | 12 | $488.00 | |
| 85007 | <1% | 6,626 | $407.73 | |
| J2704 | Injection, propofol, 10 mg | <1% | 6,724 | $406.45 |
| 87210 | <1% | 335 | $394.05 | |
| 96415 | <1% | 38 | $377.16 | |
| 80197 | <1% | 45 | $369.00 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 15,963 | $338.18 |
| 80365 | <1% | 3,196 | $335.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 689 | $321.26 |
| J3490 | Unclassified drugs | <1% | 8,334 | $304.62 |
| 82803 | <1% | 54 | $295.00 | |
| 86060 | <1% | 61 | $287.00 | |
| 84402 | <1% | 1,520 | $284.00 | |
| 82962 | <1% | 5,480 | $224.66 | |
| 72100 | <1% | 13 | $206.00 | |
| 86664 | <1% | 147 | $166.00 | |
| 73660 | <1% | 13 | $164.00 | |
| 93971 | <1% | 12 | $160.00 | |
| 85018 | <1% | 2,912 | $144.79 | |
| 86364 | <1% | 43 | $140.00 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 276 | $128.47 |
| 86901 | <1% | 7,872 | $127.23 | |
| 84155 | <1% | 2,886 | $123.19 | |
| 83540 | <1% | 6,798 | $123.01 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,533 | $114.92 |
| 96367 | <1% | 394 | $114.29 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 409 | $113.50 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 1,227 | $112.90 |
| 82465 | <1% | 22,178 | $109.43 | |
| 87077 | <1% | 857 | $103.60 | |
| 87205 | <1% | 588 | $71.00 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,686 | $65.42 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,271 | $62.56 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 9,474 | $50.02 |
| 80329 | <1% | 28 | $43.81 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 307 | $39.08 |
| E0114 | Crutches underarm, other than wood, adjustable or fixed, pair, with pads, tips and handgrips | <1% | 415 | $36.44 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 607 | $30.69 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,535 | $26.43 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,098 | $25.59 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,587 | $22.61 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,170 | $20.59 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,429 | $19.79 |
| 82166 | <1% | 12 | $15.00 | |
| 84432 | <1% | 41 | $15.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,235 | $14.91 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,823 | $14.48 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 182 | $10.35 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 247 | $10.04 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,102 | $8.94 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 184 | $8.42 |
| C1769 | Guide wire | <1% | 98 | $8.16 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 175 | $7.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 901 | $6.50 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 64 | $6.13 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 632 | $2.60 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 258 | $0.84 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 152 | $0.00 |
| 80143 | 0% | 332 | $0.00 | |
| 90749 | 0% | 73 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 411 | $0.00 |
| 80179 | 0% | 287 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 952 | $0.00 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 0% | 249 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 219 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 161 | $0.00 |
| 97161 | 0% | 539 | $0.00 | |
| 97116 | 0% | 160 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 47 | $0.00 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 12 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 83 | $0.00 |
| 85041 | 0% | 14 | $0.00 | |
| 82397 | 0% | 14 | $0.00 | |
| 84590 | 0% | 14 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 124 | $0.00 |
| 80299 | 0% | 41 | $0.00 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 54 | $0.00 |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 0% | 30 | $0.00 |
| 73562 | 0% | 29 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 16 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 17 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 140 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 33,202 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 420 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 140 | $0.00 |
| 86695 | 0% | 402 | $0.00 | |
| 96376 | 0% | 307 | $0.00 | |
| 82952 | 0% | 193 | $0.00 | |
| 74022 | 0% | 16 | $0.00 | |
| 86361 | 0% | 218 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 315 | $0.00 |
| 96368 | 0% | 41 | $0.00 | |
| 87253 | 0% | 30 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 13 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 64 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 28 | $0.00 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 13 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 16 | $0.00 |
| 76801 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSHAW, DANIEL (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Kaiser Foundation Hospitals | Honolulu, HI | $182K |
| Kaiser Foundation Health Plan, INC | Wailuku, HI | $12K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.